Vir Biotechnology Ventures Into New Territory with Appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer

Vir Biotechnology, Inc. (Nasdaq: VIR) is pleased to welcome Sasha Damouni Ellis a vital addition to the Executive Management Team as the company’s new Executive Vice President and Chief Corporate Affairs Officer. Effective July 10, 2023, Ms. Damouni Ellis will be leading the strategic corporate communications, government affairs, investor relations, and patient advocacy initiatives while establishing Vir’s corporate social responsibility and environment, social and governance initiatives. She will be reporting directly to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will provide strategic oversight across the company’s impactful activities.

Sasha Damouni Ellis is joining Vir’s executive team as a Corporate Communications and Investor Relations leader, and Dr. Marianne De Backer couldn’t be more thrilled. Sasha brings an impressive record and invaluable insights to the team as they continue their charge forward in advancing innovative therapies for the treatment of infectious diseases.

Vir is positioned with a strong clinical pipeline and a bright future, making Sasha’s position all the more crucial to its success of addressing unmet medical needs on a global scale. Sasha is honored to join the team of scientific innovators, passionate employees, and dedicated Board of Directors.

Ms. Damouni Ellis joins Vir with an extensive background in corporate affairs and investor relations. She comes to Vir from Marinus Pharmaceuticals where she served as Senior Vice President. Prior to that, she was at Bayer U.S. where she was the Director of External Communications and Media Relations, using her expertise in brand-building strategies to drive therapeutic areas such as oncology, hemophilia, cardio-pulmonary, and women’s health.

Her career began as a Senior Healthcare Journalist at Bloomberg News and then went onto launch Global Editor of BioPharm Insight, a division of the Financial Times Group, in New York and London. Ms. Damouni Ellis holds a Master of Arts from City, University of London’s Graduate School of Journalism, and a Bachelor of Arts Degree from Richmond, the American International University in London, United Kingdom.

About Vir Biotechnology

Vir Biotechnology is leading the charge in the fight against infectious diseases, with cutting-edge immunologic insights and technologies designed to augment and strengthen the body’s natural defenses. The company’s pipeline includes innovative solutions for COVID-19, hepatitis B and D, influenza A and HIV – all focused on stimulating the immune system in ways that nature has demonstrated to be effective. Investing in Vir could provide investors with a unique opportunity to make a real difference in the fight against infectious disease. Stay up to date with the latest news by visiting Vir’s website.

Forward-Looking Statements

Vir is making progress on its clinical pipeline, with potential breakthroughs that could change the medical landscape in the future. However, there is a high degree of risk associated with drug development and commercialization, and only a small number of research and development initiatives ever make it to the finish line. Vir recognizes this, and is working hard to mitigate potential risks and maximize the potential benefits of any advancements made. Factors such as unexpected safety or efficacy data, challenges in collaborating with other companies, and delays caused by external factors could all affect the progress of Vir’s pipeline. Nevertheless, Vir remains optimistic and will continue to strive for success in the future.

Leave a Comment